학술논문

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Document Type
Journal
Source
LANCET DIABETES & ENDOCRINOLOGY; MAR 2023, 11 3, p169-p181, 13p.
Subject
Language
English
ISSN
22138595